Entries by Dana Fowlkes

October 20, 2016

BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more

October 20, 2016 /0 Comments/by

August 5, 2016:

FORGE Life Science is awarded its fourth grant from the NIH National Institute for Allergy and Infectious Disease titled, ”Sirtuin Agonists as Pan-Influenza Antivirals” (1R44AI122488-01). Read more

August 5, 2016 /0 Comments/by

June 1, 2016:

FORGE Life Science secures an in-kind services investment from ShangPharma Investment Group Limited providing FORGE medicinal chemistry and DMPK contract research services from the service division of the ShangPharma group, ChemPartner, a leading contract research organization.

June 1, 2016 /0 Comments/by

October 19, 2015:

FORGE Life Science Board Chairman, Thomas Shenk is keynote speaker at the BioCentury China Healthcare Summit in Shanghai, China. His talk, “Been There, Done That, Doing It Again” tells his personal story as a serial entrepreneur from ImClone Systems to FORGE Life Science.

October 19, 2015 /0 Comments/by

August 1, 2015:

Dr. Eain Murphy, formerly Associate Professor of Virology at the Cleveland Clinic Lerner Research Institute, joins FORGE Life Science as Head of Biology.

August 1, 2015 /0 Comments/by

February 5, 2015:

FORGE Life Science is awarded its third grant from the NIH National Institute for Allergy and Infectious Disease titled, “An Antiviral to Treat Progressive Multifocal Leukoencephalopathy (PML)” (1R43AI118232-01). Read more

February 5, 2015 /0 Comments/by

December 16, 2014:

FORGE Life Science Founders, Ileana Cristea, Emre Koyuncu, and Thomas Shenk publish their breakthrough discovery that “Sirtuins Are Evolutionarily Conserved Viral Restriction Factors”. Read more

December 16, 2014 /0 Comments/by